Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.67 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835263 | 1.00 | AGTR1 (0.68) | AGTR1AGTR2GP6MME | |
| SCHEMBL2835160 | 1.00 | AGTR1 (0.68) | AGTR1AGTR2GP6MME | |
| SCHEMBL2834945 | 0.95 | AGTR1 (0.67) | AGTR1AGTR2GP6MME | |
| SCHEMBL2840108 | 0.95 | AGTR1 (0.67) | AGTR1AGTR2GP6MME | |
| SCHEMBL2834949 | 0.95 | AGTR1 (0.67) | AGTR1AGTR2GP6MME | |
| SCHEMBL2836762 | 0.95 | AGTR1 (0.68) | AGTR1AGTR2GP6MME | |
| SCHEMBL2834246 | 0.95 | AGTR1 (0.68) | AGTR1AGTR2GP6MME | |
| SCHEMBL2834250 | 0.95 | AGTR1 (0.68) | AGTR1AGTR2GP6MME | |
| SCHEMBL2836773 | 0.94 | AGTR1 (0.68) | AGTR1AGTR2GP6MME | |
| SCHEMBL2836457 | 0.94 | AGTR1 (0.68) | AGTR1AGTR2GP6MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | WANG JIANMIN | 2010-07-22 | — | — | US | claimed |
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | WANG JIANMIN | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | REN, ACE, AGTR1 | AGTR1 3/4885AGTR2 5/4885GP6 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.